DAWN
NASDAQ · Biotechnology
Day One Biopharmaceuticals I
$21.53
+0.04 (+0.19%)
Financial Highlights (FY 2026)
Revenue
158.38M
Net Income
-107,457,204
Gross Margin
89.1%
Profit Margin
-67.9%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.1% | 46.9% | 46.9% | 46.9% |
| Operating Margin | -80.8% | -22.2% | -21.0% | -17.8% |
| Profit Margin | -67.9% | -21.3% | -26.1% | -22.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 158.38M | 322.81M | 330.87M | 292.97M |
| Gross Profit | 141.15M | 151.27M | 155.05M | 137.28M |
| Operating Income | -127,907,916 | -71,658,126 | -69,386,807 | -52,102,430 |
| Net Income | -107,457,204 | -68,873,512 | -86,473,457 | -66,837,013 |
| Gross Margin | 89.1% | 46.9% | 46.9% | 46.9% |
| Operating Margin | -80.8% | -22.2% | -21.0% | -17.8% |
| Profit Margin | -67.9% | -21.3% | -26.1% | -22.8% |
| Rev Growth | — | +3.3% | -3.7% | -9.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 233.47M | 239.68M | 231.49M |
| Total Equity | — | 409.99M | 453.69M | 388.91M |
| D/E Ratio | — | 0.57 | 0.53 | 0.60 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -127,566,034 | -92,549,420 | -89,278,899 | -77,082,109 |
| Free Cash Flow | — | -81,242,335 | -91,466,852 | -93,667,658 |